Genenta Science SpA · NASDAQ:GNTA
Genenta Science SpA — Saentra Forge — Investor Presentation (November 2026)
30 slides from Genenta Science SpA's investor presentation, Nov 4, 2026
Slide 1: Saentra Forge Corporate Presentation November 2026
SAENTRA FORGE (Nasdaq: SAEN) The Next-Generation Strategic Industrial Consolidator Focused on Aerospace, Defense, National Security — including physical AI, robotics, autonomous systems, advanced sensors, cybersecurity — and Biotechnology/Biosecurity. November 2026
Slide 2: Forward-Looking Statements and Other Notices
FORWARD-LOOKING STATEMENTS AND OTHER NOTICES Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of histor
Slide 3: Saentra Forge
SAENTRA FORGE Saentra Forge1 (Nasdaq: SAEN) is a next-generation strategic industrial consolidator focused on acquiring majority or full ownership of companies operating in security–regulated sectors, with activities spanning aerospace, defense and national security — including physical AI, robotics
Slide 4: Saentra Forge at a Glance
SAENTRA FORGE AT A GLANCE 2 100% 19.9% Transactions completed in 2026 ATC – wholly-owned subsidiary Sòphia High Tech ATC (100%) and Sòphia High Tech (19.9%) Tactical defense systems · all-stock, May 2026 Space & defense components · second tranche contemplated up to 51% 4 $33M SAEN Strategic pillars
Slide 5: Industrial Consolidator
INDUSTRIAL CONSOLIDATOR October 2025 – November 2026. Twelve months from strategy to execution: two transactions completed, governance strengthened, new identity adopted. Corporate purpose extended to strategic sectors; capital Golden Power clearance; first Investment Agreement with raised from inst
Slide 6: The Strategic Pillars
THE STRATEGIC PILLARS Saentra Forge is organized around key synergistic pillars creating a diversified platform AEROSPACE DEFENSE NATIONAL BIOTECHNOLOGY SECURITY BIOSECURITY 6
Slide 7: A Structural Advantage
A STRUCTURAL ADVANTAGE In strategically regulated sectors, the barrier that deters most buyers is our entry point – not an obstacle, but a moat. 1 THE FILTER 2 THE RIGHT PROFILE 3 PROTECTED ASSETS Golden Power screens every acquisition in strategic sectors. For Italian, Nasdaq-listed, with sovereign
Slide 8: Why Now: The Opportunity
WHY NOW: THE OPPORTUNITY Italy’s defense supply chain is a vast, fragmented base of SMEs – the headline figures capture only the tip 8
Slide 9: Why Now: The Opportunity
WHY NOW: THE OPPORTUNITY Sellers in strategic sectors have fewer exit routes just as capital and demand surge into the sector Saentra Forge can act on these opportunities: the right profile to clear the filter, and a listed currency to pay for them. 9
Slide 10: Acquisition Criteria
ACQUISITION CRITERIA A disciplined filter applied to strategic scale-up – acquiring where private capital wants in but cannot easily access. 10
Slide 11: Value Creation Playbook
VALUE CREATION PLAYBOOK Acquire at private-market valuations, consolidate within a Nasdaq-listed platform, hold long-term. Value is created after closing. COMMERCIAL & INTERNATIONAL GOVERNANCE & REPORTING ACCESS TO CAPITAL INSTITUTIONAL NETWORK GROWTH • Board of Directors with Saentra Forge • Nasdaq
Slide 12: Leadership
LEADERSHIP + 30 years of experience as Chief Financial Educated at Bocconi University and Officer in various biopharmaceutical, the London School of Economics, he diagnostic, and life science companies, began his career as an Equity Analyst including Biological Dynamics, GenMark Intern at Kairos Par
Slide 13: Aerospace • Defense
€} Saentra Forge 2S. © AEROSPACE ices | © DEFENSE
Slide 14: Why Space, Why Now: The Strategic Rationale
WHY SPACE, WHY NOW: THE STRATEGIC RATIONALE The space economy is scaling rapidly, driven by commercial demand, national security priority, and sovereign investment 14
Slide 15: Sophia High Tech: Company Overview
SOPHIA HIGH TECH: COMPANY OVERVIEW What it does • Builds the critical mechanical components of space and defense systems, precision parts that hold rockets together, protect satellites in orbit, and let aircraft perform under extreme stress. Covers the entire product lifecycle: concept design & simu
Slide 16: Sophia HT: Key Figures
SOPHIA HT: KEY FIGURES The transaction • April 22, 2026 — Saentra Forge signed an Investment Agreement with Sòphia HT to reach a controlling stake through a phased two- tranche structure. • June 12, 2026 — Required Golden Power authorization obtained. • June 25, 2026 — First tranche completed follow
Slide 17: Space Manufacturing & Customers
SPACE MANUFACTURING & CUSTOMERS 17
Slide 18: Defense Market Context
€4 Saentra Forge DEFENSE MABKETCONTEXT THE DEFENSE INDUSTRIAL BASE IS EXPANDING STRUCTURALLY 5% of GDP NATO Allies committed to invest 5% of GDP annually in core defense and defense- and security-related GLOBAL MILITARY EXPENDITURE (US$ TRILLION) spending by 2035 (35% + 1.5%) Current USS, as publish
Slide 19: ATC: Company Overview
ATC: COMPANY OVERVIEW ATC “Armi Tattiche Custom” is an Italian company founded in 2019. ATC designs, engineers, and manufactures high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. Through vertical integration of design and through final quality assuran
Slide 20: ATC: The Acquisition
ATC: THE ACQUISITION • Timing: January 2026 - Initial investment agreement signed. May 2026 - Saentra Forge completed the acquisition of 100% of A.T.C. S.r.l. ("ATC") through newly issued Saentra Forge shares, preserving corporate liquidity and financial flexibility for future strategic investments
Slide 21: Biotechnology Biosecurity
€} Saentra Forge BIOTECHNOLOGY BIOSECURITY
Slide 22: Biotechnology: A Partnership-Driven Pillar
BIOTECHNOLOGY: A PARTNERSHIP-DRIVEN PILLAR A proprietary cell-therapy platform with clinical proof of concept, advanced through partnerships rather than Company-funded development. THE PLATFORM TEM-GBM PHASE 1/2a STUDY Temferon is a one-time cell therapy designed to break tumor-induced immune suppre
Slide 23: Pierluigi Paracchi, CEO
PIERLUIGI PARACCHI, CEO pierluigi.paracchi@saentra.com Saentra Forge www.saentra.com
Slide 24: Appendix
| APPENDIX
Slide 25: Board of Directors
BOARD OF DIRECTORS Dr. Galimi is a physician-executive with over Giacomo Paracchi is a Partner at LEXIA. 30 years of experience in healthcare R&D, His work primarily focuses on corporate including leadership roles in private and law, commercial contracts and corporate public biotechs as well as larg
Slide 26: Financial Profile
FINANCIAL PROFILE Cash & cash equivalents and marketable securities1 $ 33 MM Expected cash runway2 More than 12 months Number of shares outstanding3 48.2 MM Average daily volume4 1.5 MM shares 1 – December 31, 2025. 2 – For additional information see the Company’s Form 20-F filed with the SEC on Mar
Slide 27: Partnerships to Take to the Next Stage
PARTNERSHIPS TO TAKE TO THE NEXT STAGE The Company has reached key clinical milestones that it believes may enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and str
Slide 28: Potential First in Class Cell Therapy
POTENTIAL FIRST IN CLASS CELL THERAPY Temferon TM is a one-time cell therapy designed to break the tumor-induced Proprietary platform to immune suppression by enabling sustained targeted expression of therapeutic provide durable and payload inside the tumor microenvironment (TME). safe treatments fo
Slide 29: Survival Metrics in TEM-GBM Study Up to 3 Years
SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS Evaluable Patients Dosed with Temferon 25 Number of Patients survival > 1 year 19 (76%) Number of Patients survival > 2 years1 8 (32%) Number of Patients survival > 3 years 2 (8%) Survival rate at 1 and 2 years since first surgery compared favorably wi
Slide 30: Preliminary Clinical Data in uMGMT GBM
PRELIMINARY CLINICAL DATA IN µMGMT GBM • Detectable and expectedly very low levels of IFN-⍺ (pg/ml range) in plasma; • Manageable safety profile, with adverse events commonly associated with autologous stem cell transplantation and glioblastoma; SAFETY AND • No dose limiting toxicities observed to d
Saentra Forge — Investor Presentation (November 2026) on 6ix